Asset Details
Do you wish to reserve the book?
Chidamide suppresses the glycolysis of triple negative breast cancer cells partially by targeting the miR-33a-5p-LDHA axis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Chidamide suppresses the glycolysis of triple negative breast cancer cells partially by targeting the miR-33a-5p-LDHA axis
Do you wish to request the book?
Chidamide suppresses the glycolysis of triple negative breast cancer cells partially by targeting the miR-33a-5p-LDHA axis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Chidamide suppresses the glycolysis of triple negative breast cancer cells partially by targeting the miR-33a-5p-LDHA axis
2019
Overview
Triple negative breast cancer (TNBC) is one of the most aggressive types of breast cancer and has a poor prognosis. Therefore, the development of novel drugs and understanding the molecular mechanisms that may contribute to the initiation and development of TNBC are urgently required. Chidamide, a histone deacetylase inhibitor, has been reported as possessing anti-cancer properties in several cancers, however, the function of chidamide in TNBC remains to be elucidated. The present study revealed that chidamide inhibited the proliferation, colony formation and migration of TNBC cells. Experiments investigating the underlying mechanism revealed that chidamide upregulated the expression of microRNA (miR)-33a-5p in TNBC cells via RT-qPCR. Luciferase reporter assay demonstrated that miR-33a-5p was bound to the 3′-untranslated region of lactate dehydrogenase A (LDHA) and decreased the expression of LDHA in TNBC cells. In addition, chidamide suppressed the expression of LDHA and significantly decreased the glycolysis of TNBC cells. Collectively, the results of the present study demonstrated that chidamide reprogramed glucose metabolism, partially by targeting the miR-33a-5p/LDHA pathway, in TNBC. These findings indicate that chidamide may be a promising novel drug in the treatment of patients with TNBC.
Publisher
D.A. Spandidos,Spandidos Publications,Spandidos Publications UK Ltd
Subject
/ Cell Movement - drug effects
/ Cell Proliferation - drug effects
/ Enzymes
/ Female
/ Gene Expression Regulation, Neoplastic - drug effects
/ Glucose
/ Humans
/ Kinases
/ L-Lactate Dehydrogenase - genetics
/ Melanoma
/ MicroRNA
/ miRNA
/ Novels
/ Scientific equipment industry
/ Signal Transduction - drug effects
/ Studies
/ triple negative breast cancer
/ Triple Negative Breast Neoplasms - drug therapy
